Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MPI | P34949 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28852568 | 0.80 | POLB (0.53) | MAPTALDH1A1SMN1; SMN2KMT2ATDP1 | |
| SCHEMBL6034201 | 0.78 | CYP19A1 (0.57) | KMT2APKMPOLBCYP19A1 | |
| SCHEMBL6647469 | 0.78 | CYP19A1 (0.43) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6645341 | 0.78 | MAPT (0.54) | MAPTALDH1A1GLASMN1; SMN2KMT2A | |
| SCHEMBL23875581 | 0.77 | CYP19A1 (0.51) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5655760 | 0.76 | KCNJ1 (0.54) | ALDH1A1KMT2APKMPOLBCYP19A1 | |
| SCHEMBL28852534 | 0.75 | PKM (0.39) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23579167 | 0.75 | POLB (0.44) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5655128 | 0.75 | POLB (0.63) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5656114 | 0.75 | SMN1; SMN2 (0.63) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | MAPT 4101/4885ALDH1A1 2174/4885GLA 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.